Skip to main content
Top

Indian Journal of Hematology and Blood Transfusion

Issue 2/2014

Content (14 Articles)

Review Article

Rational Use of Recombinant Factor VIIa in Clinical Practice

T. K. Dutta, S. P. Verma

Review Article

Hydroxyurea in Sickle Cell Disease: Drug Review

Rohit Kumar Agrawal, Rakesh Kantilal Patel, Varsha shah, Lalit Nainiwal, Bhadra Trivedi

Original Article

Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin’s Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study

Fan Yang, Huan-Ling Zhu, Chuan He, Jian-Jun Li, Bing Xiang, Xu Cui, Jie Huang, Jie Ji, Hong-Bing Ma, Ting Liu

Original Article

Rate of Seroconversion in Repeat Blood Donors at The National Blood Centre, Kuala Lumpur

A. Nafishah, M. Nor Asiah, A. T. Nur Syimah, T. H. Mohd Zahari, A. Yasmin, M. Normi, E. Anza, M. Shahnaz, M. Y. Narazah

Original Article

Long Term Oral Anticoagulant Therapy With Warfarin: Experience With Local Patient Population in Kuwait

Husam E. El Ghousain, Mathew Thomas, Sunny Joseph Varghese, Mohamed O. Hegazi, Ramesh Kumar

Short Communication

Prophyactic Platelet Transfusion in Stable Dengue Fever Patients: Is It Really Necessary?

B. Prashantha, S. Varun, Damodar Sharat, B. V. Murali Mohan, R. Ranganatha, Shivaprasad, Manchal Naveen

Case Report

Hemolytic Disease of the Newborn Due to Anti-Jkb: Case Report and Review of the Literature

Diego Velasco Rodríguez, G. Pérez-Segura, A. Jiménez-Ubieto, M. A. Rodríguez, L. Montejano

Case Report

Chronic Neutrophilic Leukemia with V617F JAK2 Mutation

Smeeta Gajendra, Ritu Gupta, Meenal Chandgothia, Lalit Kumar, Richa Gupta, Snehal Motilal Chavan

Correspondence

Disseminated Histoplasmosis in a Patient with Aplastic Anemia

Sanjeev Kumar Sharma, Sunil Gupta, Prashant Durgapal, Anjan Mukherjee, Tulika Seth, Pravas Mishra, Manoranjan Mahapatra, Immaculata Xess, Ruma Ray, Sanjay Sharma

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine